Beyond the Hype: How Biotech Navigates the Harsh Realities of 2026Global Report·5 hours agoARQT-5.16%INCY+1.53%
Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $566,808.00 in StockMarket Beat·12 hours agoPBYI+1.49%RY+0.75%
Puma Biotechnology director Alessandra Cesano disposes of 62,150 common shares worth $566,437.45PUBT·14 hours agoPBYI+1.49%
Wellington Management Group LLP Invests $1.02 Million in Puma Biotechnology, Inc. $PBYIMarket Beat·Sep 12 at 08:32 AMPBYI+1.49%BLK+1.76%
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference | PBYI Stock NewsStockTitan·Sep 9 at 12:11 PMPBYI+1.49%
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | PBYI Stock NewsStockTitan·Sep 3 at 01:00 PMPBYI+1.49%
Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High - Still a Buy?Market Beat·Sep 2 at 08:20 PMPBYI+1.49%BLK+1.76%
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPSMarket Beat·Aug 8 at 03:41 AMPBYI+1.49%
Puma Biotech posts Q2 2026 financial results presentation webcast reportPUBT·Aug 6 at 10:20 PMPBYI+1.49%
Puma Biotechnology Q2 FY26 GAAP net income rises 38.98% to $8.2 million; revenue increases 7.82% to $56.5 millionPUBT·Aug 6 at 08:24 PMPBYI+1.49%
